CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review

Al-Mansour, 2013, Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies, Curr Hematol Malig Rep, 8, 173, 10.1007/s11899-013-0162-5 Opelz, 2004, Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transpl, 4, 222, 10.1046/j.1600-6143.2003.00325.x Leblond, 1998, Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?, J Clin Oncol, 16, 2052, 10.1200/JCO.1998.16.6.2052 Dierickx, 2018, Post-transplantation lymphoproliferative disorders in adults, N Engl J Med, 378, 549, 10.1056/NEJMra1702693 Luskin, 2015, The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder, Am J Transpl, 15, 2665, 10.1111/ajt.13324 DeStefano, 2018, Management of post-transplant lymphoproliferative disorders, Br J Haematol, 182, 330, 10.1111/bjh.15263 Jain, 2020, Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder, Br J Haematol, 189, 97, 10.1111/bjh.16304 Schuster, 2017, Chimeric antigen receptor t cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Wang, 2021, Successful treatment of pediatric refractory burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy, Cell Transpl, 30, 1, 10.1177/0963689721996649 Luttwak, 2020, Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series, Bone Marrow Transpl, 1 Dang, 2020, Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy, Pediatr Transpl, e13861 Krishnamoorthy, 2021, CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder, Am J Transpl, 21, 809, 10.1111/ajt.16367 Ibrahim, 2020, A rare case of response to chimeric antigen receptor (CAR) T cell therapy in post-transplant lymphoproliferative disorder Mamlouk, 2021, Safety of CAR T-cell therapy in kidney transplant recipients, Blood, 137, 2558, 10.1182/blood.2020008759 Strati, 2021, Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma, Blood, 10.1182/blood.2020008865 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226 Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transpl, 25, 625, 10.1016/j.bbmt.2018.12.758 Cheson, 2016, Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy, Blood, 128, 2489, 10.1182/blood-2016-05-718528 Los-Arcos, 2021, Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper, Infection, 49, 215, 10.1007/s15010-020-01521-5 van der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat Rev Drug Discov, 14, 499, 10.1038/nrd4597 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Rouphael, 2016, Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder, Clin Transpl, 30, 60, 10.1111/ctr.12659 Franke, 2017, Association of allograft rejection with reduction of immunosuppression for post-transplant lymphoproliferative disorder: analysis of a 20-year single-institutional experience, J Clin Oncol, 35, 10.1200/JCO.2017.35.15_suppl.e19047 Clatworthy, 2011, Targeting B cells and antibody in transplantation, Am J Transpl, 11, 1359, 10.1111/j.1600-6143.2011.03554.x Dragon, 2020, CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation, J Immunother Cancer, 8, 10.1136/jitc-2020-000736 Slabik, 2020, CAR-T cells targeting epstein-barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease, Mol Ther oncolytics, 18, 504, 10.1016/j.omto.2020.08.005